logo
Plus   Neg
Share
Email

Total Not To Buy Anadarko's Interests In Ghana - Quick Facts

Occidental Petroleum Corp. (OXY) announced Monday that Total S.A. (TOT) has informed Occidental that it is not interested in purchasing Anadarko Petroleum Corp.'s (APC) interests in Ghana in the current circumstances.

The Ghana assets sale was conditional upon the completion of the Algeria assets' sale. Occidental would not be in a position to sell its interests in Algeria to Total.

This was part of a Purchase and Sale Agreement entered into between Total and Occidental in August 2019 for Total to acquire Anadarko's assets in Africa. Total and Occidental have since completed the sale and purchase of the Mozambique and South Africa assets.

On May 5, 2019, Occidental entered into a binding agreement to sell Anadarko's Algeria, Ghana, Mozambique and South Africa assets to Total for $8.8 billion. The sale is contingent upon Occidental completing its acquisition of Anadarko.

On May 9, Occidental agreed to buy Anadarko in a transaction valued at $57 billion, including the assumption of Anadarko's debt.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Volkswagen Group were gaining around 3 percent in German trading after the automotive giant Thursday reported market recovery in the third quarter with improved deliveries in the month of September. For the first nine months of fiscal 2020, the company, meanwhile reported sharply lower earnings with weak revenues and sales volume. Comcast Corp. on Thursday reported a 37 percent decline in profit for the third quarter from last year, hurt primarily by revenue decline at NBCUniversal. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also declared a quarterly dividend. In the pre-market trade, CMCSA is trading at $42.83, up $0.85 or 2.02 percent. Regeneron announced positive results from its late stage COVID-19 outpatient trial, indicating that its antibody cocktail therapy significantly reduced virus levels and need for further medical attention. The trial results showed that investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints.
Follow RTT